Failure of zidovudine prophylaxis after accidental exposure to hiv-1

Joep M.A. Lange*, Charles A.B. Boucher, Carla E.M. Hollar, Ed H.H. Wiltink, Peter Reiss, Eric A. Van Royen, Marijke Roos, Sven A. Danner, Jaap Goudsmit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


ON the basis of encouraging data from two studies in animals,1,2 the manufacturer of the antiretroviral nucleoside analogue zidovudine (formerly azido--thymidine [AZT]) has initiated a placebo-controlled trial to assess the chemoprophylactic efficacy of zidovudine after occupational or nosocomial exposure to the human immunodeficiency virus type 1 (HIV-1).3,4 It is unlikely, however, that this trial will be completed soon, given the relatively low risk of infection through occupational exposure.4 In anticipation of the results of the study, several programs of zidovudine chemoprophylaxis for health care workers who have been occupationally exposed to HIV-1 have been implemented.4 The aftermath of a tragic.

Original languageEnglish
Pages (from-to)1375-1377
Number of pages3
JournalNew England Journal of Medicine
Issue number19
Publication statusPublished - 10 May 1990

Cite this